Taivex Therapeutics Corporation
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
1. T-1101: Global first-in-class Hec1/Nek2 targeted small molecule inhibitor
2. T-1201: Novel targeted small molecule-SN-38 conjugate anticancer drug
3. T-1301: Multi-targeted tyrosine kinase inhibitor
4. T-1501: Novel small molecule-DM-1 conjugate targeted anticancer drug
2. T-1201: Novel targeted small molecule-SN-38 conjugate anticancer drug
3. T-1301: Multi-targeted tyrosine kinase inhibitor
4. T-1501: Novel small molecule-DM-1 conjugate targeted anticancer drug
The content above was translated by Ai
Founded Year
2010
Unified Business No.
25104214
Status
Active
Number of Employees
0
Total Paid-in
Capital
707,399,260 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Taivex Therapeutics Inc. is a proprietary technology platforms to identify compounds that inhibit the Hec1-Nek2 interactions
The content above was translated by Ai
